• +1-646-491-9876
    • +91-20-67278686

    Search

    Diabetic Nephropathy - Pipeline Review, H1 2017

    Diabetic Nephropathy - Pipeline Review, H1 2017

    • Report Code ID: RW0001709497
    • Category Pharmaceuticals
    • No. of Pages 200
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Diabetic Nephropathy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2017, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

    Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 15, 6, 30, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

    Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 6
    List of Figures 7
    Introduction 8
    Publisher Report Coverage 8
    Diabetic Nephropathy - Overview 9
    Diabetic Nephropathy - Therapeutics Development 10
    Pipeline Overview 10
    Pipeline by Companies 11
    Pipeline by Universities/Institutes 15
    Products under Development by Companies 16
    Products under Development by Universities/Institutes 20
    Diabetic Nephropathy - Therapeutics Assessment 21
    Assessment by Target 21
    Assessment by Mechanism of Action 24
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Diabetic Nephropathy - Companies Involved in Therapeutics Development 31
    AbbVie Inc 31
    Allergan Plc 31
    Antisense Therapeutics Ltd 32
    Aptevo Therapeutics Inc 32
    Araim Pharmaceuticals Inc 33
    Arena Pharmaceuticals Inc 33
    Astellas Pharma Inc 34
    AstraZeneca Plc 34
    Bayer AG 35
    BLR Bio LLC 35
    Boehringer Ingelheim GmbH 36
    Cellmid Ltd 36
    ChemoCentryx Inc 37
    CSL Ltd 37
    Daiichi Sankyo Company Ltd 38
    DiaMedica Therapeutics Inc 38
    Dynamis Therapeutics Inc 39
    Galectin Therapeutics Inc 39
    GenKyoTex SA 40
    Gilead Sciences Inc 40
    GNI Group Ltd 41
    Islet Sciences Inc 41
    Jenrin Discovery Inc 42
    Johnson & Johnson 42
    Mallinckrodt Plc 43
    Mesoblast Ltd 43
    Mitsubishi Tanabe Pharma Corp 44
    MorphoSys AG 44
    Novartis AG 45
    Noxxon Pharma AG 45
    Omeros Corp 46
    PhiloGene Inc 46
    PhytoHealth Corp 47
    ProMetic Life Sciences Inc 47
    RegenMedTX LLC 48
    Serodus ASA 48
    Teijin Pharma Ltd 49
    Theravance Biopharma Inc 49
    Variant Pharmaceuticals Inc 50
    Vascular Pharmaceuticals Inc 50
    Vicore Pharma AB 50
    XORTX Pharma Corp 51
    Diabetic Nephropathy - Drug Profiles 52
    11-RVIVIT - Drug Profile 52
    A-717 - Drug Profile 53
    Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 54
    APD-371 - Drug Profile 55
    APX-115 - Drug Profile 56
    ASP-8232 - Drug Profile 57
    atesidorsen sodium - Drug Profile 58
    atrasentan hydrochloride - Drug Profile 66
    BI-703704 - Drug Profile 68
    BL-5923 - Drug Profile 69
    BLR-200 - Drug Profile 70
    C-21 - Drug Profile 71
    canagliflozin - Drug Profile 74
    CCX-140 - Drug Profile 81
    Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 85
    cenicriviroc mesylate - Drug Profile 87
    cibinetide - Drug Profile 95
    corticotropin - Drug Profile 98
    CSL-346 - Drug Profile 100
    Cyndacel-M - Drug Profile 101
    DM-299 - Drug Profile 103
    Drugs for Diabetic Nephropathy - Drug Profile 104
    DT-23552 - Drug Profile 105
    DYN-12 - Drug Profile 106
    emapticap pegol - Drug Profile 108
    esaxerenone - Drug Profile 111
    finerenone - Drug Profile 114
    GKT-136901 - Drug Profile 116
    GKT-831 - Drug Profile 117
    GLY-230 - Drug Profile 120
    GRMD-02 - Drug Profile 121
    GS-444217 - Drug Profile 134
    IP-9 - Drug Profile 135
    JD-5037 - Drug Profile 136
    JNJ-39933673 - Drug Profile 137
    MG-132 - Drug Profile 138
    Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 139
    MOR-107 - Drug Profile 141
    MPC-300IV - Drug Profile 142
    MT-3995 - Drug Profile 148
    Orbcel-M - Drug Profile 149
    oxypurinol - Drug Profile 150
    PBI-4050 - Drug Profile 151
    PBI-4425 - Drug Profile 158
    PBI-4547 - Drug Profile 159
    PHN-033 - Drug Profile 160
    pirfenidone - Drug Profile 161
    Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology - Drug Profile 163
    SER-150 - Drug Profile 164
    Small Molecules for Diabetic Nephropathy - Drug Profile 167
    Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 168
    SP-20202 - Drug Profile 169
    TBE-31 - Drug Profile 170
    TD-0714 - Drug Profile 171
    TD-1439 - Drug Profile 173
    TMX-049 - Drug Profile 174
    TNFR x TWEAKR - Drug Profile 175
    VAR-400 - Drug Profile 176
    VPI-2690B - Drug Profile 177
    VS-105 - Drug Profile 178
    Wnt-001 - Drug Profile 179
    XRX-108 - Drug Profile 180
    XRX-221 - Drug Profile 181
    Diabetic Nephropathy - Dormant Projects 182
    Diabetic Nephropathy - Discontinued Products 184
    Diabetic Nephropathy - Product Development Milestones 185
    Featured News & Press Releases 185
    Appendix 195
    Methodology 195
    Coverage 195
    Secondary Research 195
    Primary Research 195
    Expert Panel Validation 195
    Contact Us 195
    Disclaimer 196

    List of Tables

    Number of Products under Development for Diabetic Nephropathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Diabetic Nephropathy - Pipeline by AbbVie Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Allergan Plc, H1 2017
    Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H1 2017
    Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H1 2017
    Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H1 2017
    Diabetic Nephropathy - Pipeline by Bayer AG, H1 2017
    Diabetic Nephropathy - Pipeline by BLR Bio LLC, H1 2017
    Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Diabetic Nephropathy - Pipeline by Cellmid Ltd, H1 2017
    Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H1 2017
    Diabetic Nephropathy - Pipeline by CSL Ltd, H1 2017
    Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H1 2017
    Diabetic Nephropathy - Pipeline by GenKyoTex SA, H1 2017
    Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H1 2017
    Diabetic Nephropathy - Pipeline by GNI Group Ltd, H1 2017
    Diabetic Nephropathy - Pipeline by Islet Sciences Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Jenrin Discovery Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2017
    Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H1 2017
    Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H1 2017
    Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Diabetic Nephropathy - Pipeline by MorphoSys AG, H1 2017
    Diabetic Nephropathy - Pipeline by Novartis AG, H1 2017
    Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2017
    Diabetic Nephropathy - Pipeline by Omeros Corp, H1 2017
    Diabetic Nephropathy - Pipeline by PhiloGene Inc, H1 2017
    Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H1 2017
    Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H1 2017
    Diabetic Nephropathy - Pipeline by RegenMedTX LLC, H1 2017
    Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2017
    Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H1 2017
    Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Variant Pharmaceuticals Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H1 2017
    Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H1 2017
    Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H1 2017
    Diabetic Nephropathy - Dormant Projects, H1 2017
    Diabetic Nephropathy - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Diabetic Nephropathy - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Diabetic Nephropathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AbbVie Inc
    Allergan Plc
    Antisense Therapeutics Ltd
    Aptevo Therapeutics Inc
    Araim Pharmaceuticals Inc
    Arena Pharmaceuticals Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    Bayer AG
    BLR Bio LLC
    Boehringer Ingelheim GmbH
    Cellmid Ltd
    ChemoCentryx Inc
    CSL Ltd
    Daiichi Sankyo Company Ltd
    DiaMedica Therapeutics Inc
    Dynamis Therapeutics Inc
    Galectin Therapeutics Inc
    GenKyoTex SA
    Gilead Sciences Inc
    GNI Group Ltd
    Islet Sciences Inc
    Jenrin Discovery Inc
    Johnson & Johnson
    Mallinckrodt Plc
    Mesoblast Ltd
    Mitsubishi Tanabe Pharma Corp
    MorphoSys AG
    Novartis AG
    Noxxon Pharma AG
    Omeros Corp
    PhiloGene Inc
    PhytoHealth Corp
    ProMetic Life Sciences Inc
    RegenMedTX LLC
    Serodus ASA
    Teijin Pharma Ltd
    Theravance Biopharma Inc
    Variant Pharmaceuticals Inc
    Vascular Pharmaceuticals Inc
    Vicore Pharma AB
    XORTX Pharma Corp

    Request for Sample

    Report Url http://www.reportsweb.com//diabetic-nephropathy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//diabetic-nephropathy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//diabetic-nephropathy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments